Haier Biomedical Hosts European Partner Summit in Rome to Advance Regional Innovations
Haier Biomedical recently convened a European Partner Summit in Rome themed "Common Progress - Sharing the Future of Biomedical Innovations." The summit brought together 37 regional partners and industry leaders from 23 European countries, reflecting the company's commitment to advancing the biomedicine sector in Europe. Haier Biomedical outlined its long-term strategies for the continent and presented an expanded portfolio of laboratory solutions designed to modernize its offerings strategically.
Enrique Wang, Head of Global Markets at Haier Biomedical, emphasized the company's goal to achieve over 50% of its global revenue from international markets by 2027, with a targeted focus on increasing revenue from non-cooling sectors by 2028. This underscores Europe’s strategic importance in Haier Biomedical’s globalization strategy, focusing on localizing products, services, and support tailored to regional regulations and customer expectations.
During the presentation of the European strategy for 2026, Semir Selimovic, Director for Northern, Central, and Eastern Europe at Haier Biomedical, highlighted ongoing investments in local sales, services, and expertise to enhance the company's responsiveness and implementation capabilities in key markets. European operations have rapidly become one of Haier Biomedical's fastest-growing international regions, coinciding with the expansion of local teams and a constantly evolving product portfolio.
Among the newly unveiled products, exceptional attention was drawn to the XJ-III plasma apheresis system, which has received EU MDR certification—signifying a crucial milestone in meeting stringent European regulatory requirements. Additionally, Haier Biomedical's incubators, centrifuges, biological safety cabinets, and cooling lines are gaining significant market share due to their energy-efficient technologies and adherence to regional certification standards. This advancement aligns with the ongoing development of a comprehensive portfolio capable of supporting laboratories, hospitals, and life science institutions with robust solutions.
In his discussion about growth strategies through automation and intelligent blood management, Daniele Pericolini, Haier Biomedical's European automation solutions specialist, detailed how the company's automated biobanking solutions integrate ultra-low temperature storage with RFID support, modular automation platforms, and liquid nitrogen systems. These innovations significantly enhance sample traceability and operational efficiency, addressing challenges such as sample integrity, temperature monitoring, and high-density storage. The intelligent blood management system, U-Blood, further exemplifies this shift from traditional cold storage to interconnected real-time blood supply chain management, aiming to reduce waste, improve traceability, and support continuous transfusion workflows amidst Europe's growing emphasis on safety and digitalization initiatives.
The summit also spotlighted success stories from four European partners across Germany, Slovenia, France, and Denmark, showcasing the strong local validation of Haier Biomedical’s solutions. A long-term French partner presented a collaboratively developed biological safety cabinet tailored to French standards, deployed in more than 230 units across over 100 customers. Meanwhile, a Danish partner shared success in public tenders with a low-temperature freezer and plans to expand into additional product categories, while extensive pharmaceutical deployments in Slovenia have reinforced the company’s capabilities in managing complex multi-unit projects. Central European partners also emphasized reliability, compliance, and post-sale support as key differentiators.
The continuous growth of Haier Biomedical's European footprint is backed by robust financial results, with the company reporting revenues exceeding 2.3 billion RMB for 2025. International revenues reached 840 million RMB, constituting more than 36% of total revenues, reflecting sustained global expansion. Europe recorded double-digit growth, contributing significantly to overall international revenue increases, with AI-driven solutions and automation-related offerings comprising around 15% of total sales for the year, signaling a technology-focused transformation. These results showcase a broader shift away from hardware export towards localized solution deliveries supported by regional teams and certifications in over 18 countries.
In concluding the European Partner Summit, Haier Biomedical reaffirmed its commitment to enhancing local operations, expanding automation, and advancing life science solutions while fostering growth through collaboration with partners. By integrating global innovative capabilities with local execution in Europe, the company aims to solidify its position as a trusted solutions provider in the life sciences sector in 2026 and beyond. For further information, visit https://www.haiermedical.com/. Video available at: YouTube and Photo.
Enrique Wang, Head of Global Markets at Haier Biomedical, emphasized the company's goal to achieve over 50% of its global revenue from international markets by 2027, with a targeted focus on increasing revenue from non-cooling sectors by 2028. This underscores Europe’s strategic importance in Haier Biomedical’s globalization strategy, focusing on localizing products, services, and support tailored to regional regulations and customer expectations.
During the presentation of the European strategy for 2026, Semir Selimovic, Director for Northern, Central, and Eastern Europe at Haier Biomedical, highlighted ongoing investments in local sales, services, and expertise to enhance the company's responsiveness and implementation capabilities in key markets. European operations have rapidly become one of Haier Biomedical's fastest-growing international regions, coinciding with the expansion of local teams and a constantly evolving product portfolio.
Among the newly unveiled products, exceptional attention was drawn to the XJ-III plasma apheresis system, which has received EU MDR certification—signifying a crucial milestone in meeting stringent European regulatory requirements. Additionally, Haier Biomedical's incubators, centrifuges, biological safety cabinets, and cooling lines are gaining significant market share due to their energy-efficient technologies and adherence to regional certification standards. This advancement aligns with the ongoing development of a comprehensive portfolio capable of supporting laboratories, hospitals, and life science institutions with robust solutions.
In his discussion about growth strategies through automation and intelligent blood management, Daniele Pericolini, Haier Biomedical's European automation solutions specialist, detailed how the company's automated biobanking solutions integrate ultra-low temperature storage with RFID support, modular automation platforms, and liquid nitrogen systems. These innovations significantly enhance sample traceability and operational efficiency, addressing challenges such as sample integrity, temperature monitoring, and high-density storage. The intelligent blood management system, U-Blood, further exemplifies this shift from traditional cold storage to interconnected real-time blood supply chain management, aiming to reduce waste, improve traceability, and support continuous transfusion workflows amidst Europe's growing emphasis on safety and digitalization initiatives.
The summit also spotlighted success stories from four European partners across Germany, Slovenia, France, and Denmark, showcasing the strong local validation of Haier Biomedical’s solutions. A long-term French partner presented a collaboratively developed biological safety cabinet tailored to French standards, deployed in more than 230 units across over 100 customers. Meanwhile, a Danish partner shared success in public tenders with a low-temperature freezer and plans to expand into additional product categories, while extensive pharmaceutical deployments in Slovenia have reinforced the company’s capabilities in managing complex multi-unit projects. Central European partners also emphasized reliability, compliance, and post-sale support as key differentiators.
The continuous growth of Haier Biomedical's European footprint is backed by robust financial results, with the company reporting revenues exceeding 2.3 billion RMB for 2025. International revenues reached 840 million RMB, constituting more than 36% of total revenues, reflecting sustained global expansion. Europe recorded double-digit growth, contributing significantly to overall international revenue increases, with AI-driven solutions and automation-related offerings comprising around 15% of total sales for the year, signaling a technology-focused transformation. These results showcase a broader shift away from hardware export towards localized solution deliveries supported by regional teams and certifications in over 18 countries.
In concluding the European Partner Summit, Haier Biomedical reaffirmed its commitment to enhancing local operations, expanding automation, and advancing life science solutions while fostering growth through collaboration with partners. By integrating global innovative capabilities with local execution in Europe, the company aims to solidify its position as a trusted solutions provider in the life sciences sector in 2026 and beyond. For further information, visit https://www.haiermedical.com/. Video available at: YouTube and Photo.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.